Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Mitzi M. Gonzales Clear advanced filters

  • Gonzales et al. conducted an open-label phase 1 clinical trial of rapamycin for mild cognitive impairment and dementia due to Alzheimer’s disease. Rapamycin is not detected in cerebrospinal fluid before or after treatment, but there are changes in multiple neurodegenerative diseases and inflammatory biomarkers from baseline to post-treatment.

    • Mitzi M. Gonzales
    • Valentina R. Garbarino
    • Dean Kellogg Jr
    ResearchOpen Access
    Communications Medicine
    Volume: 5, P: 1-12

  • Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This article reports a discussion of a research Task Force on the challenges posed by the clinical research in Geroscience so that future gerotherapeutic clinical trials can be conducted successfully.

    • Yves Rolland
    • Felipe Sierra
    • Alex Zhavoronkov
    ReviewsOpen Access
    Nature Communications
    Volume: 14, P: 1-10

  • The first feasibility study of orally delivered senolytic therapy in Alzheimer’s disease reports favorable safety data and penetrance of dasatinib into the brain with a modest impact on Alzheimer’s and aging biomarkers.

    • Mitzi M. Gonzales
    • Valentina R. Garbarino
    • Miranda E. Orr
    Research
    Nature Medicine
    Volume: 29, P: 2481-2488